Sanofi (SAN FP) Winthrop Industrie withdrew its application for use of Dupixent on 24th June 2026, according to the EMA

• Sanofi Winthrop Industrie withdrew its application for the use of Dupixent in the treatment of adults with moderate-to-severe bullous pemphigoid, an autoimmune skin disease causing widespread itching and blisters affecting the skin and sometimes the inside of the mouth.

Withdrawals of regulatory applications mid-review are a familiar pattern in European drug filings: companies typically pull a submission when the agency's questions or emerging data make approval in the current cycle unlikely, preserving the option to refile rather than take a formal refusal on the record. The distinction that matters here is between a withdrawal driven by the indication-specific package and one reflecting on the underlying asset; label expansions into narrower autoimmune indications have historically been the former, leaving the core franchise economics intact. Dupixent is one of the largest revenue drivers in the sector, and past episodes of single-indication setbacks on blockbuster immunology assets have tended to be absorbed as pipeline noise rather than franchise events, with the equity reaction confined to the marginal sales contribution of the indication in question. The question the EMA's question-and-answer documentation usually answers is whether the issue was efficacy, safety, or manufacturing, since each carries a different read-across for pending filings in adjacent indications. Worth noting is whether the sponsor signals intent to resubmit, which has been the more common path, or abandons the indication entirely. The co-marketing partner's disclosures are the natural follow-on, since economics on this asset are shared.